**Supplementary Appendix**

Supplementary Appendix 1: Protocol on the management of infusion reactions

Supplementary Appendix 2: Participants experiencing more than one IRR

Supplementary Appendix 3: Proportions of infusions triggering an infusion related reaction by the cumulative number of received infusions.

Supplementary Appendix 4: Numbers of infusions triggering an infusion reaction by the cumulative number of received infusions and clinical phenotype.

**Supplementary Appendix 1: Protocol on the management of infusion reactions**



**Supplementary Appendix 2: Participants experiencing more than one IRR**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID** | **Trial** | **Infusion No.** | **Age** | **Sex at birth** | **Race** | **Severity Grade** | **Treatment Assignment** | **IRR Category** | **Discontinuation status** |
| 1 | HVTN 703 / HPTN 081 | 1 | 24 | Female | Black | Moderate | VRC01 10mg/kg  | Other (nasal congestion, throat irritation and difficulty swallowing) | No change |
| 1 | HVTN 703 / HPTN 081 | 3 | 24 | Female | Black | Moderate | VRC01 10mg/kg  | Other (flushing and pruritus) | No change |
| 1 | HVTN 703 / HPTN 081 | 6 | 25 | Female | Black | Mild | VRC01 10mg/kg  | Urticarial reaction | Permanently Discontinued |
| 2 | HVTN 703 / HPTN 081 | 3 | 28 | Female | Black | Moderate | VRC01 10mg/kg | Dyspnea without rash | No change |
| 2 | HVTN 703 / HPTN 081 | 9 | 29 | Female | Black | Moderate | VRC01 10mg/kg | Urticarial reaction | Permanently Discontinued |
| 3 | HVTN 703 / HPTN 081 | 4 | 26 | Female | Black | Moderate | VRC01 10mg/kg | Other reaction (Infusion related reaction) | No change |
| 3 | HVTN 703 / HPTN 081 | 5 | 26 | Female | Black | Moderate | VRC01 10mg/kg | Dyspnea without rash | Permanently Discontinued |
| 4 | HVTN 703 / HPTN 081 | 2 | 33 | Female | Black | Mild | VRC01 10mg/kg | Other (chest discomfort) | No change |
| 4 | HVTN 703 / HPTN 081 | 3 | 33 | Female | Black | Mild | VRC01 10mg/kg | Dyspnea without rash | No change |
| 5 | HVTN 703 / HPTN 081 | 3 | 22 | Female | Black | Mild | VRC01 10mg/kg | Dyspnea without rash | No change |
| 5 | HVTN 703 / HPTN 081 | 5 | 23 | Female | Black | Mild | VRC01 10mg/kg | Dyspnea without rash | No change |
| 5 | HVTN 703 / HPTN 081 | 10 | 24 | Female | Black | Mild | VRC01 10mg/kg | Other (flushing, throat irritation and continous coughing) | No change |
| 6 | HVTN 703 / HPTN 081 | 5 | 34 | Female | Black | Mild | VRC01 10mg/kg | Other reaction (Infusion related reaction) | No change |
| 6 | HVTN 703 / HPTN 081 | 7 | 34 | Female | Black | Moderate | VRC01 10mg/kg | Other reaction (Infusion related reaction) | No change |
| 7 | HVTN 703 / HPTN 081 | 3 | 23 | Female | Black | Mild | VRC01 10mg/kg | Other reaction (Infusion related reaction) | No change |
| 7 | HVTN 703 / HPTN 081 | 4 | 23 | Female | Black | Mild | VRC01 10mg/kg | Other reaction (Infusion related reaction) | No change |
| 8 | HVTN 703 / HPTN 081 | 4 | 33 | Female | Black | Moderate | VRC01 10mg/kg | Other (itchy maculo-papular rash) | No change |
| 8 | HVTN 703 / HPTN 081 | 5 | 33 | Female | Black | Mild | VRC01 10mg/kg | Urticarial reaction | Permanently Discontinued |
| 9 | HVTN 703 / HPTN 081 | 1 | 22 | Female | Black | Mild | VRC01 10mg/kg  | Other (generalised pruritus) | No change |
| 9 | HVTN 703 / HPTN 081 | 2 | 22 | Female | Black | Severe | VRC01 10mg/kg  | Urticarial reaction | Permanently Discontinued |
| 10 | HVTN 703 / HPTN 081 | 1 | 21 | Female | Black | Mild | VRC01 30mg/kg | Other reaction (Infusion related reaction) | No change |
| 10 | HVTN 703 / HPTN 081 | 10 | 23 | Female | Black | Mild | VRC01 30mg/kg | Dyspnea without rash | Not Applicable |
| 11 | HVTN 703 / HPTN 081 | 1 | 24 | Female | Black | Mild | VRC01 30mg/kg | Other (erythematous rash on trunk) | No change |
| 11 | HVTN 703 / HPTN 081 | 2 | 24 | Female | Black | Moderate | VRC01 30mg/kg | Urticarial reaction | Permanently Discontinued |
| 12 | HVTN 703 / HPTN 081 | 3 | 22 | Female | Black | Mild | VRC01 30mg/kg  | Other (flushing, chest discomfort and headache) | No change |
| 12 | HVTN 703 / HPTN 081 | 10 | 23 | Female | Black | Mild | VRC01 30mg/kg  | Other (flushing) | Not Applicable |
| 13 | HVTN 703 / HPTN 081 | 1 | 25 | Female | Black | Moderate | VRC01 30mg/kg  | Other (generalised pruritus) | No change |
| 13 | HVTN 703 / HPTN 081 | 3 | 26 | Female | Black | Moderate | VRC01 30mg/kg  | Other (generalised pruritus) | No change |
| 13 | HVTN 703 / HPTN 081 | 4 | 26 | Female | Black | Moderate | VRC01 30mg/kg  | Other (generalised pruritus) | No change |
| 13 | HVTN 703 / HPTN 081 | 5 | 26 | Female | Black | Mild | VRC01 30mg/kg  | Other (generalised pruritus) | No change |
| 14 | HVTN 704 / HPTN 085 | 1 | 24 | Female | Multi-racial | Mild | VRC01 30mg/kg  | Urticarial reaction\* | No change |
| 14 | HVTN 704 / HPTN 085 | 2 | 24 | Female | Multi-racial | Mild | VRC01 30mg/kg  | Urticarial reaction | Permanently Discontinued |
| 15 | HVTN 703 / HPTN 081 | 4 | 35 | Female | Black | Mild | Placebo | Other reaction (Infusion related reaction) | No change |
| 15 | HVTN 703 / HPTN 081 | 5 | 35 | Female | Black | Mild | Placebo | Other (flushing, dizziness and continous coughing) | No change |
| 16 | HVTN 704 / HPTN 085 | 2 | 24 | Male | Other | Mild | Placebo  | Other reaction (Pruritus) | No change |
| 16 | HVTN 704 / HPTN 085 | 3 | 24 | Male | Other | Mild | Placebo  | Other reaction (Pruritus) | Permanently Discontinued |

**\***Participant did not disclose that they had an urticarial reaction that developed at home post-infusion hence infusion was not discontinued then.

**Supplementary Appendix 3: Proportions of infusions triggering an infusion related reaction by the cumulative number of received infusions.**

|  |  |  |
| --- | --- | --- |
|   | **HVTN 704/HPTN 085**  | **HVTN 703/HPTN 081**  |
| **Received** **Infusion #**  | **Number of Infusions**  | **Number of IRRs**  | **Proportion (%)  (95% CI)**  | **Number of Infusions**  | **Number of IRRs**  | **Proportion (%)  (95% CI)**  |
| 1  | 2699  | 18  | 0.67 (0.42, 1.05)  | 1924  | 34  | 1.77 (1.27, 2.46)  |
| 2  | 2596  | 4  | 0.15 (0.06, 0.40)  | 1851  | 19  | 1.03 (0.66, 1.60)  |
| 3  | 2533  | 12  | 0.47 (0.27, 0.83)  | 1800  | 14  | 0.78 (0.46, 1.30)  |
| 4  | 2463  | 4  | 0.16 (0.06, 0.42)  | 1754  | 12  | 0.68 (0.39, 1.19)  |
| 5  | 2413  | 3  | 0.12 (0.04, 0.36)  | 1705  | 12  | 0.70 (0.40, 1.23)  |
| 6  | 2365  | 2  | 0.08 (0.02, 0.31)  | 1660  | 6  | 0.36 (0.17, 0.79)  |
| 7  | 2314  | 0  | 0.00 (0.00, 0.17)  | 1617  | 4  | 0.25 (0.10, 0.63)  |
| 8  | 2256  | 3  | 0.13 (0.05, 0.39)  | 1568  | 3  | 0.19 (0.07, 0.56)  |
| 9  | 2179  | 1  | 0.05 (0.01, 0.26)  | 1521  | 5  | 0.33 (0.14, 0.77)  |
| 10  | 2043  | 2  | 0.10 (0.03, 0.36)  | 1407  | 2  | 0.14 (0.04, 0.52)  |

**Supplementary Appendix 4: Numbers of infusions triggering an infusion reaction by the cumulative number of received infusions and clinical phenotype.**

|  |  |  |
| --- | --- | --- |
|  | **HVTN 704/HPTN 085** | **HVTN 703/HPTN 081** |
|  |  | **Number (%) of infusion related reactions** |  | **Number (%) of infusion related reactions** |
| **Received Infusion #** | **Number of Infusions** | **Urticaria** | **Dyspnea with Rash** | **Dyspnea without Rash** | **Other** | **Number of Infusions** | **Urticaria** | **Dyspnea with Rash** | **Dyspnea without Rash** | **Other** |
| 1 | 2699 | 13 (0.48) | 0 (0.00) | 0 (0.00) | 5 (0.19) | 1924 | 24 (1.25) | 0 (0.00) | 0 (0.00) | 10 (0.52) |
| 2 | 2596 | 2 (0.08) | 1 (0.04) | 0 (0.00) | 1 (0.04) | 1851 | 7 (0.38) | 0 (0.00) | 5 (0.27) | 7 (0.38) |
| 3 | 2533 | 5 (0.20) | 2 (0.08) | 1 (0.04) | 4 (0.16) | 1800 | 0 (0.00) | 1 (0.06) | 3 (0.17) | 10 (0.56) |
| 4 | 2463 | 3 (0.12) | 0 (0.00) | 1 (0.04) | 0 (0.00) | 1754 | 3 (0.17) | 0 (0.00) | 1 (0.06) | 8 (0.46) |
| 5 | 2413 | 0 (0.00) | 0 (0.00) | 0 (0.00) | 3 (0.12) | 1705 | 3 (0.18) | 0 (0.00) | 5 (0.29) | 4 (0.23) |
| 6 | 2365 | 1 (0.04) | 0 (0.00) | 1 (0.04) | 0 (0.00) | 1660 | 1 (0.06) | 0 (0.00) | 2 (0.12) | 3 (0.18) |
| 7 | 2314 | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1617 | 1 (0.06) | 0 (0.00) | 2 (0.12) | 1 (0.06) |
| 8 | 2256 | 1 (0.04) | 0 (0.00) | 1 (0.04) | 1 (0.04) | 1568 | 1 (0.06) | 0 (0.00) | 0 (0.00) | 2 (0.13) |
| 9 | 2179 | 1 (0.05) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1521 | 1 (0.07) | 0 (0.00) | 2 (0.13) | 2 (0.13) |
| 10 | 2043 | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (0.10) | 1407 | 0 (0.00) | 0 (0.00) | 0 (0.00) | 2 (0.14) |
|  |  |  |  |  |  |  |  |  |  |  |